chuminhua2020-06-01 20:30
5/30,Menlo Therapeutics公司$Menlo Therapeutics(MNLO)$ 宣布,美国FDA已批准其全资子公司Foamix Pharmaceuticals开发的米诺环素局部疗法Zilxi(1.5% minocyline,FMX103)上市,治疗酒渣鼻成人患者。新闻稿指出,Zilxi是首款获得美国FDA批准治疗酒渣鼻成人患者的米诺环素局部疗法。Zilxi是该公...查看全文
$Menlo Therapeutics(MNLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040293 Size: 4 KB 网页链接
$Menlo Therapeutics(MNLO)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-20-075684 Act: 34 Size: 1 MB 网页链接
$Menlo Therapeutics(MNLO)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-20-075687 Act: 34 Size: 563 KB 网页链接
$Menlo Therapeutics(MNLO)$ 内部交易: 2020-06-09,10% Owner,PERCEPTIVE ADVISORS LLC ,买入,2702702普通股, $1.85
$Menlo Therapeutics(MNLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-016198 Size: 8 KB 网页链接
$Menlo Therapeutics(MNLO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000899243-20-016191 Size: 7 KB 网页链接
$Menlo Therapeutics(MNLO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001213900-20-014713 Act: 34 Size: 50 KB 网页链接
$Menlo Therapeutics(MNLO)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-20-166752 Act: 34 Size: 65 KB 网页链接
$Menlo Therapeutics(MNLO)$ PRE 14A Other preliminary proxy statements Accession Number: 0001104659-20-072078 Act: 34 Size: 1 MB 网页链接
$Menlo Therapeutics(MNLO)$ 8-K Current report, items 4.01 and 9.01 Accession Number: 0001104659-20-072056 Act: 34 Size: 30 KB 网页链接